Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 86,457 shares, an increase of 70.1% from the December 15th total of 50,833 shares. Based on an average trading volume of 99,391 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.8% of the company’s shares are sold short. Currently, 0.8% of the company’s shares are sold short. Based on an average trading volume of 99,391 shares, the days-to-cover ratio is presently 0.9 days.

Analysts Set New Price Targets

A number of equities analysts have commented on BFRI shares. Benchmark reaffirmed a “buy” rating on shares of Biofrontera in a research note on Friday, November 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Biofrontera in a report on Thursday, October 30th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Biofrontera has a consensus rating of “Hold” and a consensus price target of $2.75.

Biofrontera Price Performance

NASDAQ BFRI opened at $0.81 on Thursday. The stock has a market capitalization of $9.43 million, a P/E ratio of -0.50 and a beta of 0.59. The firm’s 50-day moving average is $0.81 and its two-hundred day moving average is $0.89. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.24.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. Biofrontera had a negative net margin of 47.28% and a negative return on equity of 1,104.09%. The business had revenue of $6.99 million for the quarter, compared to the consensus estimate of $7.00 million. As a group, analysts anticipate that Biofrontera will post -3.01 EPS for the current year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. AIGH Capital Management LLC lifted its position in Biofrontera Inc. (NASDAQ:BFRI) by 33.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 974,525 shares of the company’s stock after buying an additional 242,370 shares during the quarter. AIGH Capital Management LLC owned approximately 9.61% of Biofrontera worth $693,000 at the end of the most recent reporting period. 10.08% of the stock is currently owned by institutional investors.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.